2024 was pivotal for TCR therapies. Following the commercial approval for Adaptimmune’s Tecelra, positive clinical readouts, and FIH trials from Immatics, Triumvira, Affini-T, CDR-Life, and TScan, along with a wealth of investment and partnerships amounting to over $700M, it’s time to come together to relish in these breakthroughs, while pouring this energy into expanding TCR treatment potential. The 6th TCR-Based Therapies Summit returns as the only TCR-specific platform for industry experts to join forces to share the technical insights to transform discovery, translation, R&D, and clinical development for cell- and biologic-based approaches.